Information for Investors
A private company active since 2013 and registered in the UK, Ancon welcomes enquires from potential investors. Please contact us.
Ancon develops ground-breaking detection technologies, with applications in many fields. Our vision is to save lives and make a difference to society from the early, accurate and actionable detection of trace amounts of volatile organic compounds from a single, affordable test. To date Ancon has concentrated on applications in the security and Healthcare sectors where a significant difference can be made with our approach.
The company has four distinct groups of proprietary technologies which offer significant performance advantages compared with alternative technologies. Each of the technologies can either be integrated separately with a range of other technologies or integrated with other Ancon technologies to form a complete analysis system.
Technologies have been developed for the detection of explosives, chemical weapons, narcotics and contraband. Technologies are proprietary and patented.
Ancon’s technologies offer outstanding sensitivity (up to 1000 times more sensitive than currently deployed technologies) and high specificity supporting low false alarm rates.
Detectors are exceptionally small and are designed to be handheld or wearable. Levels of sensitivity would enable detection of target materials at a distance.
Markets include airport security, large public events, and critical infrastructure protection, and first responder support.
Diagnosis of Disease
Ancon has successfully combined detection technologies with innovative AI and Machine Learning (ML) techniques to detect infectious diseases through breath analysis and saliva swab analysis.
Conventional breath analysis techniques identify and search for specific markers of target diseases (such as cancers and bacterial and viral infections). This involves focussing on a small number of biomarkers and discarding much of the analysis data. This limited approach is often confounded by the complexity of breath. Target biomarkers are frequently masked by specific characteristics of individuals (for example their ethnicity or medical history) and the presence of chemicals in breath originating from the background environment.
Ancon takes a different approach. Applying its proprietary AI and ML techniques, all the available data from the breath or swab sample is analysed to identify subtle patterns, characteristic of disease, which are undetectable by other techniques. Trials have demonstrated high levels of specificity and sensitivity.
The effectiveness of these techniques has been shown in differentiating flu and bacterial infections through breath analysis, and the detection of Covid 19 infection through breath and saliva swab analysis.